UpFrontPSMA Trial: Lutetium-PSMA Plus Docetaxel Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
• The UpFrontPSMA trial demonstrated that adding lutetium-PSMA to docetaxel significantly improved undetectable PSA rates at 48 weeks in mHSPC patients.
• The study also showed improvements in key secondary endpoints like PSA progression-free survival and freedom from castration resistance with the lutetium-PSMA combination.
• Treatment with lutetium-PSMA did not increase overall toxicity or negatively impact quality of life, suggesting a potential role in mHSPC management.
• The ongoing PSMAddition Phase III trial will further evaluate lutetium-PSMA's utility in mHSPC, potentially changing the standard of care.
© Copyright 2025. All Rights Reserved by MedPath